The patent was issued on February 28, 2023 by the U.S. Patent Office, and protects the composition and dosage of safranol in the encapsulated saffron extract.
A saffron stigma extract from Activ’Inside (Bordeaux, France), called Safr’Inside, has obtained a new patent in the United States. The patent was issued on February 28, 2023 by the U.S. Patent Office, and protects the composition and dosage of safranol in the encapsulated saffron extract. Prior to this, Activ’Inside has secured patents for its saffron extract in Europe, Malaysia, and South Africa.
“Obtaining this patent is a new official recognition of the high added value of Safr'Inside, our encapsulated saffron extract featuring a very high safranol content: 0.2% [as measured] by HPLC” said Benoit Lemaire, CEO of Activ’Inside, in a press release. The extract is made using a unique encapsulation technology called Techcare that protects saffron from alterations and preserved its native composition to ensure a full spectrum product. This is why Safr’Inside is able to offer a high concentration of safranol content.
According to Activ’Inside, the company has conducted seven studies, including in vivo, ex-vivo, and clinical studies, that have demonstrated the ability of Safr’Inside to modulate serotonin, pointing to its potential impact on stress, sleep, menopause, premenstrual syndrome, and digestion; all of which serotonin is involved in. Further studies are underway, amounting to $3.5 million investment.